<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00375336</url>
  </required_header>
  <id_info>
    <org_study_id>IGA MH NR/8306-5</org_study_id>
    <nct_id>NCT00375336</nct_id>
  </id_info>
  <brief_title>Risk Factors Associated With Calcification of the Aortic Valve</brief_title>
  <official_title>Risk Markers of Coronary Artery Disease Associated With Calcific Aortic Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is&#xD;
&#xD;
        -  to determine the degree of endothelial dysfunction and inflammation in calcific aortic&#xD;
           valve disease associated with coronary artery disease(CAD).&#xD;
&#xD;
        -  to determine whether there is relationship between calcium metabolism and calcific&#xD;
           aortic valve disease associated with CAD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease, mainly coronary artery disease, causes more than one half of deaths&#xD;
      in the developed countries. Only recently, calcific aortic valve disease, was proved to&#xD;
      belong to the family of atherosclerosis. It is associated with higher cardiovascular&#xD;
      morbidity and mortality, the cause of which is not entirely clear. The link to significant&#xD;
      coronary artery disease, probably, is of highest importance.&#xD;
&#xD;
      We compare groups of patients with coronary artery disease and calcific stenotic, sclerotic&#xD;
      or intact aortic valve. The aim is to assess and compare their risk profile to verify our&#xD;
      hypothesis that, within significant coronary artery disease, calcific aortic valve identifies&#xD;
      a subgroup of patients with higher cardiovascular risk, assessed by endothelial dysfunction&#xD;
      and the two year follow-up of cardiovascular events on optimally set treatment.&#xD;
&#xD;
      Further, we study the possible association of valvular calcification and calcium metabolism&#xD;
      in patients with normal kidney function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Aortic Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and plasma specimens retained at -80 deg. C&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients admitted to hospital for evaluation due to common causes like dyspnea,&#xD;
        chest pain, fatigue or syncope, who fulfilled the two inclusion criteria: 1/&#xD;
        angiographically significant CAD, and 2/ AS (mean transvalvular aortic gradient ≥30 mm Hg)&#xD;
        or nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) or had normal aortic valve as&#xD;
        diagnosed by echocardiography.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  significant stenosis (more than 50% diameter stenosis) of one or more coronary&#xD;
             arteries&#xD;
&#xD;
          -  aortic sclerosis (group 1) or stenosis (AVA &lt; 1cm2/m2, or mean gradient ≥ 30 mmHg)&#xD;
             (group 2) or normal aortic valve (group 3)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Rheumatic heart disease (defined as aortic stenosis with commissural fusion +&#xD;
             rheumatic mitral valve disease)&#xD;
&#xD;
          -  Status post aortic valve replacement&#xD;
&#xD;
          -  Congenital complex heart disease (except bicuspid aortic valve)&#xD;
&#xD;
          -  Moderate to severe aortic insufficiency (grade &gt; 2/4)&#xD;
&#xD;
          -  Marfan syndrome&#xD;
&#xD;
          -  Infective endocarditis&#xD;
&#xD;
          -  Hypertrophic obstruction cardiomyopathy&#xD;
&#xD;
          -  Acute coronary syndrome within less than three months&#xD;
&#xD;
          -  Severe heart failure, NYHA class IV&#xD;
&#xD;
          -  Severe locomotion disability&#xD;
&#xD;
          -  Renal failure requiring dialysis&#xD;
&#xD;
          -  Significant systemic disease or other disease severely limiting the patient prognosis&#xD;
             (e.g. known cancer, liver cirrhosis)&#xD;
&#xD;
          -  Primary hyperparathyroidism&#xD;
&#xD;
          -  Patient non-compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katerina Linhartova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles University of Prague, School of Medicine Pilsen, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roman Cerbak, Prof,MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Cardiovascular and Transplantation Surgery, Brno, Czech Republic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles University of Prague, School of Medicine, Plzen</name>
      <address>
        <city>Plzen</city>
        <zip>304060</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <reference>
    <citation>Linhartová K, Filipovský J, Cerbák R, Sterbáková G, Hanisová I, Beránek V. Severe aortic stenosis and its association with hypertension: analysis of clinical and echocardiographic parameters. Blood Press. 2007;16(2):122-8.</citation>
    <PMID>17612911</PMID>
  </reference>
  <reference>
    <citation>Ferda J, Linhartová K, Kreuzberg B. Comparison of the aortic valve calcium content in the bicuspid and tricuspid stenotic aortic valve using non-enhanced 64-detector-row-computed tomography with prospective ECG-triggering. Eur J Radiol. 2008 Dec;68(3):471-5. Epub 2007 Oct 24.</citation>
    <PMID>17961946</PMID>
  </reference>
  <reference>
    <citation>Linhartová K, Beránek V, Sefrna F, Hanisová I, Sterbáková G, Pesková M. Aortic stenosis severity is not a risk factor for poststenotic dilatation of the ascending aorta. Circ J. 2007 Jan;71(1):84-8.</citation>
    <PMID>17186983</PMID>
  </reference>
  <results_reference>
    <citation>Linhartová K, Veselka J, Sterbáková G, Racek J, Topolcan O, Cerbák R. Parathyroid hormone and vitamin D levels are independently associated with calcific aortic stenosis. Circ J. 2008 Feb;72(2):245-50.</citation>
    <PMID>18219161</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>September 11, 2006</study_first_submitted>
  <study_first_submitted_qc>September 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2006</study_first_posted>
  <last_update_submitted>December 31, 2008</last_update_submitted>
  <last_update_submitted_qc>December 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ivana Ratajova</name_title>
    <organization>Charles University, School of Medicine Plzen</organization>
  </responsible_party>
  <keyword>Aortic valve</keyword>
  <keyword>Calcification</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Calcium metabolism</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

